-
EP2927690
European procedure
Extract from the Register of European Patents
EP About this file: EP2927690
| EP2927690 - Anti-carbamylated protein antibodies and the risk for arthritis [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 01.09.2023 Database last updated on 08.04.2026 | |
| Former | The patent has been granted Status updated on 23.09.2022 | ||
| Former | Grant of patent is intended Status updated on 05.07.2022 | ||
| Former | Examination is in progress Status updated on 07.02.2017 | Most recent event Tooltip | 19.12.2025 | Lapse of the patent in a contracting state New state(s): TR | published on 21.01.2026 [2026/04] | Applicant(s) | For all designated states Academisch Ziekenhuis Leiden h.o.d.n. LUMC Albinusdreef 2 2333 ZA Leiden / NL | [2015/41] | Inventor(s) | 01 /
Trouw, Leendert Adrianus c/o Albinusdreef 2 2333 ZA Leiden / NL | 02 /
Toes, Reinaldus Everardus Maria c/o Albinusdreef 2 2333 ZA Leiden / NL | 03 /
Huizinga, Thomas Willem Johannes c/o Albinusdreef 2 2333 ZA Leiden / NL | 04 /
van Veelen, Petrus Antonius c/o Albinusdreef 2 2333 ZA Leiden / NL | 05 /
Cerami, Anthony c/o Albinusdreef 2 2333 ZA Leiden / NL | 06 /
Shi, Jing c/o Albinusdreef 2 2333 ZA Leiden / NL | [2022/43] |
| Former [2015/41] | 01 /
Trouw, Leendert Adrianus c/o Albinusdreef 2 2333 ZA Leiden / NL | ||
| 02 /
Toes, Reinaldus Everardus Maria c/o Albinusdreef 2 2333 ZA Leiden / NL | |||
| 03 /
Huizinga, Thomas Willem Johannes c/o Albinusdreef 2 2333 ZA Leiden / NL | Representative(s) | V.O. P.O. Box 87930 2508 DH Den Haag / NL | [2015/41] | Application number, filing date | 15154208.1 | 01.02.2012 | [2015/41] | Priority number, date | EP20110153046 | 02.02.2011 Original published format: EP 11153046 | EP20110182399 | 22.09.2011 Original published format: EP 11182399 | [2015/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2927690 | Date: | 07.10.2015 | Language: | EN | [2015/41] | Type: | B1 Patent specification | No.: | EP2927690 | Date: | 26.10.2022 | Language: | EN | [2022/43] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 22.06.2015 | Classification | IPC: | G01N33/564 | [2015/41] | CPC: |
G01N33/564 (EP,US);
G01N33/6854 (EP,US);
G01N2333/75 (US);
G01N2440/00 (US);
G01N2800/101 (EP,US);
G01N2800/102 (EP,US);
G01N2800/104 (EP,US);
G01N2800/105 (EP,US);
G01N2800/107 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/41] | Title | German: | Anticarbamylierte Protein-Antikörper und Arthritisgefahr | [2015/41] | English: | Anti-carbamylated protein antibodies and the risk for arthritis | [2015/41] | French: | Anticorps de protéines anti-carbamylées et le risque d'arthrite | [2015/41] | Examination procedure | 06.02.2015 | Examination requested [2015/41] | 06.04.2016 | Amendment by applicant (claims and/or description) | 29.09.2016 | Despatch of a communication from the examining division (Time limit: M06) | 14.03.2017 | Reply to a communication from the examining division | 12.09.2017 | Despatch of a communication from the examining division (Time limit: M04) | 15.01.2018 | Reply to a communication from the examining division | 03.05.2018 | Despatch of a communication from the examining division (Time limit: M04) | 05.09.2018 | Reply to a communication from the examining division | 30.11.2018 | Despatch of a communication from the examining division (Time limit: M04) | 02.04.2019 | Reply to a communication from the examining division | 07.10.2019 | Despatch of a communication from the examining division (Time limit: M06) | 30.03.2020 | Reply to a communication from the examining division | 13.10.2021 | Date of oral proceedings | 22.11.2021 | Despatch of a communication from the examining division (Time limit: M04) | 28.01.2022 | Minutes of oral proceedings despatched | 15.03.2022 | Reply to a communication from the examining division | 06.07.2022 | Communication of intention to grant the patent | 20.09.2022 | Fee for grant paid | 20.09.2022 | Fee for publishing/printing paid | 20.09.2022 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP12704564.9 / EP2671078 | Opposition(s) | 27.07.2023 | No opposition filed within time limit [2023/40] | Fees paid | Renewal fee | 06.02.2015 | Renewal fee patent year 03 | 06.02.2015 | Renewal fee patent year 04 | 29.01.2016 | Renewal fee patent year 05 | 31.01.2017 | Renewal fee patent year 06 | 31.01.2018 | Renewal fee patent year 07 | 22.01.2019 | Renewal fee patent year 08 | 21.01.2020 | Renewal fee patent year 09 | 19.01.2021 | Renewal fee patent year 10 | 18.01.2022 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CY | 01.02.2012 | HU | 01.02.2012 | AL | 26.10.2022 | AT | 26.10.2022 | BG | 26.10.2022 | CZ | 26.10.2022 | DK | 26.10.2022 | EE | 26.10.2022 | FI | 26.10.2022 | HR | 26.10.2022 | LT | 26.10.2022 | LV | 26.10.2022 | MC | 26.10.2022 | NL | 26.10.2022 | PL | 26.10.2022 | RO | 26.10.2022 | RS | 26.10.2022 | SE | 26.10.2022 | SI | 26.10.2022 | SK | 26.10.2022 | SM | 26.10.2022 | TR | 26.10.2022 | NO | 26.01.2023 | GR | 27.01.2023 | IE | 01.02.2023 | LU | 01.02.2023 | IS | 26.02.2023 | PT | 27.02.2023 | BE | 28.02.2023 | CH | 28.02.2023 | LI | 28.02.2023 | [2026/04] |
| Former [2025/39] | CY | 01.02.2012 | |
| HU | 01.02.2012 | ||
| AL | 26.10.2022 | ||
| AT | 26.10.2022 | ||
| BG | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IE | 01.02.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| BE | 28.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2025/36] | CY | 01.02.2012 | |
| AL | 26.10.2022 | ||
| AT | 26.10.2022 | ||
| BG | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IE | 01.02.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| BE | 28.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2024/51] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| BG | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IE | 01.02.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| BE | 28.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2024/12] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IE | 01.02.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| BE | 28.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2024/08] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IE | 01.02.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2023/51] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SI | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2023/49] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| LU | 01.02.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2023/48] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| CH | 28.02.2023 | ||
| LI | 28.02.2023 | ||
| Former [2023/44] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| MC | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/38] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SK | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/37] | AL | 26.10.2022 | |
| AT | 26.10.2022 | ||
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/35] | AT | 26.10.2022 | |
| CZ | 26.10.2022 | ||
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RO | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/34] | AT | 26.10.2022 | |
| DK | 26.10.2022 | ||
| EE | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/33] | AT | 26.10.2022 | |
| DK | 26.10.2022 | ||
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| SM | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/26] | AT | 26.10.2022 | |
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| PL | 26.10.2022 | ||
| RS | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| IS | 26.02.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/24] | AT | 26.10.2022 | |
| FI | 26.10.2022 | ||
| HR | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/23] | AT | 26.10.2022 | |
| FI | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| LV | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| GR | 27.01.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/22] | AT | 26.10.2022 | |
| FI | 26.10.2022 | ||
| LT | 26.10.2022 | ||
| NL | 26.10.2022 | ||
| SE | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| PT | 27.02.2023 | ||
| Former [2023/20] | LT | 26.10.2022 | |
| NL | 26.10.2022 | ||
| NO | 26.01.2023 | ||
| Former [2023/17] | NL | 26.10.2022 | Documents cited: | Search | [A] WO2009007846 (BIRKELAND INNOVASJON AS et al.) | [A] US2008305990 (BRINES MICHAEL et al.) | [A] US2007087380 (VAN VENROOIJ WALTHERUS JACOBUS et al.) | [A] WO2009032722 (CLEVELAND CLINIC FOUNDATION et al.) | [XDA] MYDEL PIOTR ET AL: "Carbamylation-Dependent Activation of T Cells: A Novel Mechanism in the Pathogenesis of Autoimmune Arthritis", JOURNAL OF IMMUNOLOGY, vol. 184, no. 12, June 2010 (2010-06-01), pages 6882 - 6890, XP002631888, ISSN: 0022-1767 DOI: http://dx.doi.org/10.4049/âjimmunol.1000075 | [A] KLARESKOG LARS ET AL: "Immunity to citrullinated proteins in rheumatoid arthritis", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, vol. 26, 1 January 2008 (2008-01-01), pages 651 - 675, XP002503053, ISSN: 0732-0582, DOI: 10.1146/ANNUREV.IMMUNOL.26.021607.090244 DOI: http://dx.doi.org/10.1146/annurev.immunol.26.021607.090244 | Examination | S. JAISSON ET AL: "Carbamylation-Derived Products: Bioactive Compounds and Potential Biomarkers in Chronic Renal Failure and Atherosclerosis", CLINICAL CHEMISTRY., vol. 57, no. 11, 28 October 2011 (2011-10-28), WASHINGTON, DC., pages 1499 - 1505, XP055526731, ISSN: 0009-9147, DOI: 10.1373/clinchem.2011.163188 DOI: http://dx.doi.org/10.1373/clinchem.2011.163188 | by applicant | VENROOIJ ET AL.: "Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis", THE NETHERLANDS JOURNAL OF MEDICINE, vol. 60, 2002, pages 383 - 388, XP009509547 | KLARESKOG L; RONNELID J; LUNDBERG K; PADYUKOV L; ALFREDSSON L.: "Immunity to citrullinated proteins in rheumatoid arthritis", ANNU REV IMMUNOL, vol. 26, 2008, pages 651 - 75, XP002503053, DOI: doi:10.1146/annurev.immunol.26.021607.090244 DOI: http://dx.doi.org/10.1146/annurev.immunol.26.021607.090244 | SCHELLEKENS ET AL., J. CLIN. INVEST., vol. 101, 1998, pages 271 - 281 | PRUIJN GJ; WIIK A; VAN VENROOIJ WJ., ARTHRITIS RES THER. 2010, vol. 12, no. 1, 15 February 2010 (2010-02-15), pages 203 | VAN GAALEN FA; VISSER H; HUIZINGA TW.: "A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis", ANN RHEUM DIS., vol. 64, no. 10, October 2005 (2005-10-01), pages 1510 - 2, XP003024770, DOI: doi:10.1136/ARD.2004.035089 DOI: http://dx.doi.org/10.1136/ARD.2004.035089 | KALLBERG H; PADYUKOV L; PLENGE RM; RONNELID J; GREGERSEN PK; VAN DER HELM-VAN MIL AH ET AL.: "Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis", AM J HUM GENET, vol. 80, no. 5, 2007, pages 867 - 75 | VAN DER HELM-VAN MIL AH; VERPOORT KN; BREEDVELD FC; TOES RE; HUIZINGA TW.: "Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis", ARTHRITIS RES THER, vol. 7, no. 5, 2005, pages R949 - R958, XP002503056, DOI: doi:10.1186/AR1767 DOI: http://dx.doi.org/10.1186/AR1767 | VAN DER WOUDE D.; YOUNG A; JAYAKUMAR K; MERTENS BJ; TOES RE; VAN DER HD ET AL.: "Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts", ARTHRITIS RHEUM, vol. 60, no. 8, 2009, pages 2262 - 71 | VISSER K; VERPOORT KN; VAN DH; VAN DER KOOIJ SM; ALLAART CF; TOES RE ET AL.: "Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis", ANN RHEUM DIS, vol. 67, no. 8, 2008, pages 1194 - 5 | COHEN SB; EMERY P; GREENWALD MW; DOUGADOS M; FURIE RA; GENOVESE MC ET AL.: "Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks", ARTHRITIS RHEUM, vol. 54, no. 9, 2006, pages 2793 - 806, XP055032105, DOI: doi:10.1002/art.22025 DOI: http://dx.doi.org/10.1002/art.22025 | QUARTUCCIO L; FABRIS M; SALVIN S; ATZENI F; SARACCO M; BENUCCI M ET AL.: "Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis", RHEUMATOLOGY (OXFORD, vol. 48, no. 12, 2009, pages 1557 - 9 | GYORGY B; TOTH E; TARCSA E; FALUS A; BUZAS EI.: "Citrullination: a posttranslational modification in health and disease", INT J BIOCHEM CELL BIOL, vol. 38, no. 10, 2006, pages 1662 - 77, XP024987505, DOI: doi:10.1016/j.biocel.2006.03.008 DOI: http://dx.doi.org/10.1016/j.biocel.2006.03.008 | WANG Y; WYSOCKA J; SAYEGH J; LEE YH; PERLIN JR; LEONELLI L ET AL.: "Human PAD4 regulates histone arginine methylation levels via demethylimination", SCIENCE, vol. 306, no. 5694, 2004, pages 279 - 83, XP002400988, DOI: doi:10.1126/science.1101400 DOI: http://dx.doi.org/10.1126/science.1101400 | LI P; LI M; LINDBERG MR; KENNETT MJ; XIONG N; WANG Y.: "PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps", J EXP MED, vol. 207, no. 9, 2010, pages 1853 - 62 | MYDEL P; WANG Z; BRISSLERT M; HELLVARD A; DAHLBERG LE; HAZEN SL ET AL.: "Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis", J IMMUNOL, vol. 184, no. 12, 2010, pages 6882 - 90, XP002631888, DOI: doi:10.4049/ jimmunol.1000075 DOI: http://dx.doi.org/10.4049/âjimmunol.1000075 | SIRPAL S.: "Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease", CLIN SCI (LOND, vol. 116, no. 9, 2009, pages 681 - 95 | WANG Z; NICHOLLS SJ; RODRIGUEZ ER; KUMMU O; HORKKO S; BARNARD J ET AL.: "Protein carbamylation links inflammation, smoking, uremia and atherogenesis", NAT MED, vol. 13, no. 10, 2007, pages 1176 - 84, XP002505709, DOI: doi:10.1038/NM1637 DOI: http://dx.doi.org/10.1038/NM1637 | TURUNEN S; KOIVULA MK; RISTELI L; RISTELI J.: "Anticitrulline antibodies can be caused by homocitrulline-containing proteins in rabbits", ARTHRITIS RHEUM, vol. 62, no. 11, 2010, pages 3345 - 52 | VAN AKEN J.; VAN BILSEN JH; ALLAART CF; HUIZINGA TW; BREEDVELD FC.: "The Leiden Early Arthritis Clinic", CLIN EXP RHEUMATOL, vol. 21, no. 31, 2003, pages S100 - S105 | ARNETT FC; EDWORTHY SM; BLOCH DA; MCSHANE DJ; FRIES JF; COOPER NS ET AL.: "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", ARTHRITIS RHEUM, vol. 31, no. 3, 1988, pages 315 - 24 | VERPOORT KN; CHEUNG K; LOAN-FACSINAY A; VAN DER HELM-VAN MIL AH; DE VRIES-BOUWSTRA JK; ALLAART CF ET AL.: "Fine specificity of the anti- citrullinated protein antibody response is influenced by the shared epitope alleles", ARTHRITIS RHEUM, vol. 56, no. 12, 2007, pages 3949 - 52, XP002601413, DOI: doi:10.1002/ART.23127 DOI: http://dx.doi.org/10.1002/ART.23127 | VAN DER HELM-VAN MIL AH; LE CS; VAN DH; BREEDVELD FC; TOES RE; HUIZINGA TW.: "A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions", ARTHRITIS RHEUM, vol. 56, no. 2, 2007, pages 433 - 40 | VAN DONGEN H; VAN AKEN J; LARD LR; VISSER K; RONDAY HK; HULSMANS HM ET AL.: "Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial", ARTHRITIS RHEUM, vol. 56, no. 5, 2007, pages 1424 - 32, XP055179418, DOI: doi:10.1002/art.22525 DOI: http://dx.doi.org/10.1002/art.22525 | WILLEMZE A ET AL.: "The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens", ARTHRITIS RHEUM, vol. 63, 2011, pages 1823 - 1832 | VAN DER LINDEN MP ET AL.: "Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis", ARTHRITIS RHEUM, vol. 60, 2009, pages 2242 - 2247 | BERLYNE GM: "Carbamylated proteins and peptides in health and in uremia", NEPHRON, vol. 79, 1998, pages 125 - 130 | MASSON-BESSIERE C ET AL.: "The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin", J IMMUNOL, vol. 166, 2001, pages 4177 - 4184, XP002341132 | SCHELLEKENS GA ET AL.: "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies", J CLIN INVEST, vol. 101, 1998, pages 273 - 281, XP000749589, DOI: doi:10.1172/JCI1316 DOI: http://dx.doi.org/10.1172/JCI1316 | ALETAHA D ET AL.: "The 2010 American College of Rheumatology / European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis", ARTHRITIS AND RHEUMATISM, 2010 | HILL JA ET AL.: "Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, 2008, pages 967 - 979 | KUHN KA ET AL.: "Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis", J CLIN INVEST, vol. 116, 2006, pages 961 - 973, XP055223271, DOI: doi:10.1172/JCI25422 DOI: http://dx.doi.org/10.1172/JCI25422 | UYSAL H ET AL.: "Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis", J EXP MED, 2009 | CLAVEL C ET AL.: "Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen", ARTHRITIS RHEUM, vol. 58, 2008, pages 678 - 688 | LU MC ET AL.: "Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production", ARTHRITIS RHEUM, vol. 62, 2010, pages 1213 - 1223, XP055153592, DOI: doi:10.1002/art.27386 DOI: http://dx.doi.org/10.1002/art.27386 | SCHUERWEGH AJM ET AL.: "Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, 2010, pages 2586 - 2591 | TROUW LA ET AL.: "Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways", ARTHRITIS RHEUM, vol. 60, 2009, pages 1923 - 1931 | LINN-RASKER SP ET AL.: "Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles", ANN RHEUM DIS, vol. 65, 2006, pages 366 - 371 | VAN GAALEN FA ET AL.: "Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis", ARTHRITIS RHEUM, vol. 50, 2004, pages 2113 - 2121 | VERPOORT KN ET AL.: "Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis", ARTHRITIS RHEUM, vol. 52, 2005, pages 3058 - 3062 | VERPOORT KN ET AL.: "Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles", ARTHRITIS RHEUM, vol. 56, 2007, pages 3949 - 3952, XP002601413, DOI: doi:10.1002/ART.23127 DOI: http://dx.doi.org/10.1002/ART.23127 | VAN DER HELM-VAN MIL AH ET AL.: "A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions", ARTHRITIS RHEUM, vol. 56, 2007, pages 433 - 440 | VAN DONGEN H ET AL.: "Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial", ARTHRITIS RHEUM, vol. 56, 2007, pages 1424 - 1432, XP055179418, DOI: doi:10.1002/art.22525 DOI: http://dx.doi.org/10.1002/art.22525 | DE ROOY DPC ET AL.: "Predicting arthritis outcomesGCowhat can be learned from the Leiden Early Arthritis Clinic", RHEUMATOLOGY, vol. 50, 2011, pages 93 - 100 | ARNETT FC ET AL.: "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", ARTHRITIS RHEUM, vol. 31, 1988, pages 315 - 324 | SUWANNALAI P ET AL.: "Annals of the Rheumatic Diseases", vol. 70, 2011, article "Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens", pages: 373 - 379 | VERPOORT KN ET AL.: "Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles", ARTHRITIS AND RHEUMATISM, vol. 56, 2007, pages 3949 - 3952, XP002601413, DOI: doi:10.1002/ART.23127 DOI: http://dx.doi.org/10.1002/ART.23127 | VAN DER HEIJDE D: "How to read radiographs according to the Sharp/van der Heijde method", JOURNAL OF RHEUMATOLOGY, vol. 27, 2000, pages 261 - 263 |